Logo image of ACER

ACER THERAPEUTICS INC (ACER) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ACER - US00444P1084 - Common Stock

0.9 USD
+0.03 (+3.41%)
Last: 11/8/2023, 8:19:05 PM
0.8005 USD
-0.1 (-11.06%)
After Hours: 11/8/2023, 8:19:05 PM
Fundamental Rating

0

ACER gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. ACER may be in some trouble as it scores bad on both profitability and health. ACER does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ACER had negative earnings in the past year.
  • In the past year ACER has reported a negative cash flow from operations.
ACER Yearly Net Income VS EBIT VS OCF VS FCFACER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

  • ACER has a worse Return On Assets (-225.71%) than 92.72% of its industry peers.
Industry RankSector Rank
ROA -225.71%
ROE N/A
ROIC N/A
ROA(3y)-141.6%
ROA(5y)-120.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACER Yearly ROA, ROE, ROICACER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400 600 800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ACER so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACER Yearly Profit, Operating, Gross MarginsACER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

  • ACER does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ACER has more shares outstanding than it did 1 year ago.
  • ACER has a worse debt/assets ratio than last year.
ACER Yearly Shares OutstandingACER Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
ACER Yearly Total Debt VS Total AssetsACER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -25.07, we must say that ACER is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -25.07, ACER is not doing good in the industry: 91.75% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -25.07
ROIC/WACCN/A
WACC9.13%
ACER Yearly LT Debt VS Equity VS FCFACER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

  • ACER has a Current Ratio of 0.19. This is a bad value and indicates that ACER is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ACER has a Current ratio of 0.19. This is amonst the worse of the industry: ACER underperforms 97.09% of its industry peers.
  • ACER has a Quick Ratio of 0.19. This is a bad value and indicates that ACER is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ACER's Quick ratio of 0.19 is on the low side compared to the rest of the industry. ACER is outperformed by 96.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
ACER Yearly Current Assets VS Current LiabilitesACER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

  • The earnings per share for ACER have decreased strongly by -88.64% in the last year.
  • ACER shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-88.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, ACER will show a very strong growth in Earnings Per Share. The EPS will grow by 35.01% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y55.45%
EPS Next 2Y44%
EPS Next 3Y35.01%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACER Yearly Revenue VS EstimatesACER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2021 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
ACER Yearly EPS VS EstimatesACER Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ACER. In the last year negative earnings were reported.
  • Also next year ACER is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACER Price Earnings VS Forward Price EarningsACER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACER Per share dataACER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

  • ACER's earnings are expected to grow with 35.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44%
EPS Next 3Y35.01%

More info and screens

0

5. Dividend

5.1 Amount

  • ACER does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACER THERAPEUTICS INC

NASDAQ:ACER (11/8/2023, 8:19:05 PM)

After market: 0.8005 -0.1 (-11.06%)

0.9

+0.03 (+3.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-15
Earnings (Next)03-25
Inst Owners1.19%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner Change0%
Market Cap22.01M
Revenue(TTM)N/A
Net Income(TTM)-26.24M
Analysts80
Price Target1.53 (70%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.22%
Min EPS beat(2)-43.08%
Max EPS beat(2)55.52%
EPS beat(4)2
Avg EPS beat(4)8%
Min EPS beat(4)-51.19%
Max EPS beat(4)70.76%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-86.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.66
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0
BVpS-0.69
TBVpS-1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -225.71%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-141.6%
ROA(5y)-120.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 259.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -25.07
F-Score0
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)116.99%
Cap/Depr(5y)196.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.19%
EPS Next Y55.45%
EPS Next 2Y44%
EPS Next 3Y35.01%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-91.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15924.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22323.8%
OCF growth 3YN/A
OCF growth 5YN/A

ACER THERAPEUTICS INC / ACER FAQ

Can you provide the ChartMill fundamental rating for ACER THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 0 / 10 to ACER.


What is the valuation status of ACER THERAPEUTICS INC (ACER) stock?

ChartMill assigns a valuation rating of 1 / 10 to ACER THERAPEUTICS INC (ACER). This can be considered as Overvalued.


What is the profitability of ACER stock?

ACER THERAPEUTICS INC (ACER) has a profitability rating of 0 / 10.


Can you provide the financial health for ACER stock?

The financial health rating of ACER THERAPEUTICS INC (ACER) is 0 / 10.


What is the earnings growth outlook for ACER THERAPEUTICS INC?

The Earnings per Share (EPS) of ACER THERAPEUTICS INC (ACER) is expected to grow by 55.45% in the next year.